The invention relates to biomarkers which are useful for the diagnosis and prediction of atypical parkinsonism in mammalian animals such as humans. In particular, the invention relates to the use of lysosomal network proteins chosen from Early Endosomal Antigen 1 (EEA1); Lysosomal-associated membrane protein 1 (LAMP-1); Lysosomal-associated membrane protein 2 (LAMP-2); Microtubule-associated protein light chain 3 (LC3);and Lysozymeas biomarkers in methods and kits for diagnosing, predicting or treating atypical parkinsonism in mammals. The invention further relates to methods for identifying compounds which are useful for the diagnosis, prediction or treatment of atypical parkinsonism.
